Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | SGMS1 | Q86VZ5 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902960 | 0.93 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2AKR1C3TP53LMNA | |
| SCHEMBL4895584 | 0.92 | LMNA (0.51) | ALDH1A1SMN1; SMN2AKR1C3TP53LMNA | |
| SCHEMBL4906213 | 0.90 | MMP2 (0.53) | ALDH1A1SMN1; SMN2AKR1C3TP53LMNA | |
| SCHEMBL4905124 | 0.90 | ALDH1A1 (0.55) | ALDH1A1AKR1C3TP53LMNAMAPT | |
| SCHEMBL4895764 | 0.89 | MAPT (0.54) | ALDH1A1SMN1; SMN2AKR1C3TP53LMNA | |
| SCHEMBL4904019 | 0.89 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2AKR1C3TP53LMNA | |
| SCHEMBL4906442 | 0.87 | MAPT (0.50) | ALDH1A1SMN1; SMN2AKR1C3TP53LMNA | |
| SCHEMBL5378800 | 0.86 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2MEN1KMT2APKM | |
| SCHEMBL4899749 | 0.86 | ERBB2 (0.50) | ALDH1A1SMN1; SMN2AKR1C3MAPTTBXA2R | |
| SCHEMBL4902713 | 0.85 | PKM (0.52) | ALDH1A1SMN1; SMN2AKR1C3TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | ALDH1A1 2664/4885SMN1; SMN2 3271/4885AKR1C3 1604/4885 |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | ALDH1A1 2956/4885SMN1; SMN2 3404/4885AKR1C3 1645/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | ALDH1A1 2956/4885SMN1; SMN2 3404/4885AKR1C3 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.